United States misc health and allied services industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Top Misc Health And Allied Services Stocks in USA

Name: Top Misc Health And Allied Services Stocks in USA comparison snapshot
Creator: Fliar BI Prism

Five U.S.-listed misc health and allied services names, read through one evidence stack: market path, official filing history, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderDaVita · 48

Strongest available pathDaVita · +51.5%

Widest latest marginPHCO · 20.7%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DVA · NYSE

DaVita

A U.S.-listed issuer classified by the SEC in Misc Health And Allied Services

Founded 1979WILMINGTON$11.31B market cap

View full Companies Radar profile

48Cautious

Snapshot price$176.1as of page date

Monthly-close return+51.5%five-year window

FY2020 revenue$11.04BDAVITA INC.

Net margin7.0%FY2020

P/E snapshot14.9xone ratio, not a verdict

Prism attention72.5%share across these five

Filing track recordRevenue, USD billions

+3.1%

FY2018–FY2020 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.5%

52-week position51% through range

$101.0$247.5

News mentions4.7K

Community mentions825partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position22/100
Capital-event signal39/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 17 M&A involvements, 6 asset-acquisition events and 7 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PGNY · Nasdaq

Progyny

A U.S.-listed issuer classified by the SEC in Misc Health And Allied Services

Founded 2008New York City, New York$1.97B market cap

View full Companies Radar profile

42Cautious

Snapshot price$25.66as of page date

Monthly-close return-54.2%five-year window

FY2025 revenue$1.29BProgyny, Inc.

Net margin4.5%FY2025

P/E snapshot27.9xone ratio, not a verdict

Prism attention14.5%share across these five

Filing track recordRevenue, USD billions

+157.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 26.7%

52-week position56% through range

$16.10$33.06

News mentions931

Community mentions84partial coverage

U.S.-scope patents41

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal67/100
Management stability90/100
Market position5/100
Capital-event signal20/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CCEL · NYSE

Cryo-Cell

A U.S.-listed issuer classified by the SEC in Misc Health And Allied Services

Founded 1989Oldsmar, Florida$33.6M market cap

View full Companies Radar profile

29Avoid

Snapshot price$4.17as of page date

Monthly-close return-65.6%five-year window

FY2025 revenue$0.03BCRYO CELL INTERNATIONAL INC

Net margin-7.7%FY2025

P/E snapshot208.2xone ratio, not a verdict

Prism attention3.6%share across these five

Filing track recordRevenue, USD billions

+9.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.2%

52-week position63% through range

$2.72$5.01

News mentions233

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal47/100
Management stability70/100
Market position8/100
Capital-event signal0/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4PFHO · OTCQB

PHCO

A U.S.-listed issuer classified by the SEC in Misc Health And Allied Services

Founded 1970Irvine, California$13.2M market cap

View full Companies Radar profile

27Avoid

Snapshot price$1.03as of page date

Monthly-close return+15.7%five-year window

FY2025 revenue$0.01BPACIFIC HEALTH CARE ORGANIZATION INC

Net margin20.7%FY2025

P/E snapshot12.9xone ratio, not a verdict

Prism attention1.0%share across these five

Filing track recordRevenue, USD billions

+24.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.6%

52-week position33% through range

$0.80$1.49

News mentions63

Community mentions0partial coverage

U.S.-scope patents1236

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal43/100
Management stability70/100
Market position0/100
Capital-event signal0/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5AGL · NYSE

agilon health

A U.S.-listed issuer classified by the SEC in Misc Health And Allied Services

Founded 2016Long Beach, California$1.47B market cap

View full Companies Radar profile

25Avoid

Snapshot price$87.47as of page date

Monthly-close return-86.7%five-year window

FY2025 revenue$5.93Bagilon health, inc.

Net margin-6.6%FY2025

P/E snapshot42.6xone ratio, not a verdict

Prism attention8.4%share across these five

Filing track recordRevenue, USD billions

+223.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 34.1%

52-week position64% through range

$7.48$133.0

News mentions537

Community mentions12partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 14/100higher means more observed risk

Earnings signal33/100
Management stability90/100
Market position10/100
Capital-event signal15/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 4 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

DaVita

+51.5%

PHCO

+15.7%

Progyny

-54.2%

Cryo-Cell

-65.6%

agilon health

-86.7%

Latest revenue

USD billions, official filing scope shown on each company card.

DaVita

$11.04B

agilon health

$5.93B

Progyny

$1.29B

Cryo-Cell

$0.03B

PHCO

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

PHCO

20.7%

DaVita

7.0%

Progyny

4.5%

agilon health

-6.6%

Cryo-Cell

-7.7%

Prism news attention

Normalized share across these five names; attention is not quality.

DaVita

72.5%

Progyny

14.5%

agilon health

8.4%

Cryo-Cell

3.6%

PHCO

1.0%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized misc health and allied services news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

DaVita leads the conversation

It holds 72.5% of measured misc health and allied services news attention and also carries the basket's largest revenue base at $11.04B.

Price path

DaVita leads the available price paths

Its monthly-close return is +51.5% for the five-year window. At the other end, agilon health is -86.7% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

PHCO has the widest latest margin

Its FY2025 net margin is 20.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

PHCO shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 12.9x while its five-year window price return is +15.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DVA

DaVita

4,651available Prism news records

Prism top themes

Price action & investor response

185

Macro demand & rates

163

Earnings & financial performance

103

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+48.5%772 latest 12m vs 520 prior 12m

Machine-classified coverage tone

72.4% positive+8.8 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 47kidney dialysis center 46renal dialysis services 44dialysis treatment unit 40hemodialysis clinic 32outpatient dialysis facility 31treasury bonds 26bond yields 26

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · PGNY

Progyny

931available Prism news records

Prism top themes

Price action & investor response

142

Earnings & financial performance

Legal, arbitration & regulatory

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+14.8%217 latest 12m vs 189 prior 12m

Machine-classified coverage tone

88.4% positive+20.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 36stock performance 36stock surge 18reproductive technology ethics 16share price 14earnings report 13ivf stimulation protocols 10grants for infertility 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-10-04–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DVA

DaVita

825 mentions

Workplace and hiring

291

Products, pricing and logistics

181

Stock and valuation

157

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 825 records remained after filtering.

PGNY

Progyny

84 mentions

Products, pricing and logistics

Stock and valuation

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 84 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DVA

DaVita

through 2026-02-03

Earnings releases 29Leadership changes 11Company announcements 7M&A 5Business contracts 3

2026-02-03
Earnings releases
The Colorado-based medical technology concern reported earnings per share of $3.40 for the fourth quarter of 2025, beating analysts’ consensus forecast of $3.24.
2025-12-11
Leadership changes
Steve Phillips will serve as Chief Strategy Officer, CSO, effective immediately.
2025-12-05
M&A
The deal involves four separate acquisitions from Fresenius Medical Care for a total purchase price of US$300 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PGNY

Progyny

through 2026-03-23

Earnings releases 22Lawsuits 3Leadership changes 3Business contracts 2Company announcements 2

2026-03-23
Company announcements
While the product is being launched now from a commercialization standpoint, Schoenhaus noted—and Anevski agreed—that the company expects to go live with the product in 2027, when it would begin to reap revenue.
2025-12-02
Earnings releases
Progyny shares have delivered a 60% total return over the trailing twelve months as of Dec. 1, 2025, with the company reporting ~$1.27 billion in revenue and ~$56.6 million in net income over the last year.
2025-01-16
Leadership changes
Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women’s health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CCEL

Cryo-Cell

through 2026-04-21

Earnings releases 13

2026-04-21
Earnings releases
The company reported ($0.47) earnings per share (EPS) for the quarter.
2026-04-14
Earnings releases
The Company reported net income of approximately $47,000 or $0.01 per basic and diluted common share for the three months ended February 28, 2026, compared to net income of approximately $283,000 , or $0.03 per basic and diluted common share for the same period in 2025.
2026-02-27
Earnings releases
Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PFHO

PHCO

through 2025-11-04

Earnings releases 16

2025-11-04
Earnings releases
The Company reported total revenues of $1,586,984 for the quarter ended September 30, 2025, compared to $1,500,837 for the quarter ended September 30, 2024.
2025-07-31
Earnings releases
The Company reported total revenues of $1,726,541 for the quarter ended June 30, 2025, compared to $1,541,087 for the quarter ended June 30, 2024.
2025-05-02
Earnings releases
The Company reported total revenues of $1,818,814 for the quarter ended March 31, 2025, compared to $1,397,831 for the quarter ended March 31, 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AGL

agilon health

through 2026-02-25

Lawsuits 23Earnings releases 8M&A 4Leadership changes 3Listing / IPO 3

2026-02-25
Earnings releases
Total revenue of $1.57 billion in the fourth quarter 2025 increased 3% compared to $1.52 billion in the fourth quarter 2024.
2026-02-23
Lawsuits
According to the complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges on behalf of purchasers of agilon health, inc. (NYSE: AGL) common shares between February 26, 2025 and August 4, 2025, that the defendants violated Federal Securities Laws.
2025-11-07
Regulatory
The New York Stock Exchange (the “NYSE”) issued a notice (the “Notice”) on November 5, 2025 informing the Company that it is no longer in compliance with its continued listing standards because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Misc Health And Allied Services Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary misc health and allied services news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

healthcare services market

10 sources50.0% extraction confidence

2024 extracted base$3.20T–$9.82T

2028 extracted forecast$6.26T–$9.82T

Implied source CAGR7.0%

aging populationtechnological advancementsincreasing use of telemedicine

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, United States, Nauru. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Misc Health And Allied Services news pulse

294,856available Prism news records

Latest 12m volume+25.2%140984 vs 112609 records

Positive classified tone38.0%+3.7 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching allied, health, healthcare. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

political aspects of public health

26,141

public administration challenges

25,652

crisis management in governance

20,808

celebrity health and wellness updates

15,682

public health and safety regulations

13,413

government public health governance

10,419

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

public health funding 6,808public health orders vaccines 6,467vaccine policy controversies 6,426vaccine mandate legislation 5,873vaccine mandate compliance 5,754vaccine policy ethics 5,649vaccine decision-making 5,399anti-vaccination sentiment 5,119

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

aging population

10 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

political aspects of public health

26,141 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

17,822 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

rising healthcare costs

6,020 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+25.2% news volume

The latest 12 months contain 140,984 matched records versus 112,609 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

38.0% positive · +3.7pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 8090 (Misc Health And Allied Services). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Misc Health And Allied Services Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

DaVita leads the readiness ranking

Its Prism readiness score is 48/100, the highest in this five-company comparison.

Open DaVita in Companies Radar

Scale and margin leadership sit with DaVita and PHCO

DaVita has the largest displayed latest revenue at $11.04B; PHCO has the widest displayed latest margin at 20.7%.

Open DaVita in Companies Radar Open PHCO in Companies Radar

Comparisons

Strongest versus weakest available price path

DaVita is +51.5% for its five-year window; agilon health is -86.7% for its five-year window.

Open DaVita in Companies Radar Open agilon health in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $11.04B for DaVita to $0.01B for PHCO. Entity and filing-period labels remain visible on the company cards.

Open DaVita in Companies Radar Open PHCO in Companies Radar

Anomalies

agilon health has the widest attention-readiness rank gap

It ranks #3 by measured news attention (8.4%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open agilon health in Companies Radar

agilon health shows a price-operating divergence to inspect

Its displayed filing-revenue change is +223.6% while its available monthly-close return is -86.7%. The signs differ, but the two measures cover different windows and do not establish causality.

Open agilon health in Companies Radar

Explanations

Attention measures coverage volume, not quality

DaVita's 72.5% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open DaVita in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open DaVita's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 48/100 score.

Open DaVita in Companies Radar

Stress-test the largest divergence before forming a view

Compare agilon health's profile with DaVita's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open agilon health in Companies Radar Open DaVita in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.